Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment

@article{Baricich2018SafetyPO,
  title={Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment},
  author={Alessio Baricich and Alessandro Picelli and Andrea Santamato and Stefano Carda and Alessandro de Sire and Nicola Smania and Carlo Cisari and Marco Invernizzi},
  journal={Clinical Drug Investigation},
  year={2018},
  volume={38},
  pages={991-1000}
}
Botulinum toxin type A (BoNT-A) is considered the gold standard for the treatment of focal post-stroke spasticity (PSS). However, a recently published study estimated that a significant percentage of patients affected by PSS could benefit from higher doses of BoNT-A than those permitted by current directives in the countries studied. Several studies have reported the use of high doses of BoNT-A in the management of patients affected by severe PSS; however, the most important adverse effect of… CONTINUE READING